News
-
-
-
COMMUNIQUÉ DE PRESSE
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
IGC Pharma, Inc. will participate in BIO Partnering @ JPM alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. The management team will showcase recent partnerships and achievements -
-
-
COMMUNIQUÉ DE PRESSE
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
IGC Pharma, Inc. expands clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease, to evaluate disease-modifying potential targeting amyloid plaque and tau tangles -
-
-
COMMUNIQUÉ DE PRESSE
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28% -
